<div><div></div><div>On December 9, 2025, Akero Therapeutics, Inc. announced significant changes to its board and executive team following the consummation of a merger. All previous directors and executive officers resigned, and new appointments were made as per the merger agreement.<div><table><tbody><tr><td>Individual</td><td>Andrew Cheng, M.D., Ph.D.</td><td>Jane Henderson</td><td>Seth L. Harrison, M.D., Ph.D.</td><td>Graham L. Walmsley, M.D., Ph.D.</td><td>Yuan Xu, Ph.D.</td><td>Mark T. Iwicki</td><td>Tomas Heyman</td><td>Judy Chou, Ph.D.</td><td>Scott Gangloff</td><td>Patrick Lamy</td><td>Timothy Rolph, D.Phil.</td><td>William White, J.D.</td><td>Catriona Yale</td><td>Jonathan Young, J.D., Ph.D.</td><td>John Kuckelman</td><td>Daniel Bohsen</td><td>Steve Benz</td></tr><tr><td>Role</td><td>Director/Executive Officer</td><td>Director</td><td>Director</td><td>Director</td><td>Director</td><td>Director</td><td>Director</td><td>Director</td><td>Executive Officer</td><td>Executive Officer</td><td>Executive Officer</td><td>Executive Officer</td><td>Executive Officer</td><td>Executive Officer</td><td>Director</td><td>Director/President and Treasurer</td><td>Director</td></tr><tr><td>Type of Change</td><td>Resigned</td><td>Resigned</td><td>Resigned</td><td>Resigned</td><td>Resigned</td><td>Resigned</td><td>Resigned</td><td>Resigned</td><td>Removed</td><td>Removed</td><td>Removed</td><td>Removed</td><td>Removed</td><td>Removed/Re-appointed</td><td>Appointed</td><td>Appointed</td><td>Appointed</td></tr><tr><td>Effective Date</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td><td>Effective Time of Merger</td></tr><tr><td>Reason</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td><td>Merger Agreement</td></tr><tr><td>Replacement Info</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Re-appointed as Assistant Treasurer</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td></tr><tr><td>Background Details</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Board/Committee Role Changes</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td></tr></tbody></table></div>Original SEC Filing: Akero Therapeutics, Inc. [ AKRO ] - 8-K - Dec. 09, 2025<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

AKRO

Akero Therapeutics announced major board and executive changes after a merger on December 9, 2025. All previous directors and executive officers resigned, and new appointments were made according to the merger agreement. The changes were effective at the time of the merger, but replacement details were not disclosed.

Akero Therapeutics Announces Board and Executive Changes Following Merger